TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average Price Target from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $40.67.

A number of research analysts have commented on TGTX shares. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright boosted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th.

TG Therapeutics Stock Up 4.0 %

TGTX stock opened at $32.20 on Friday. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The business’s 50 day simple moving average is $29.62 and its 200 day simple moving average is $23.96. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $5.01 billion, a PE ratio of -321.97 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 earnings per share. As a group, research analysts anticipate that TG Therapeutics will post 0.17 EPS for the current year.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently modified their holdings of the business. NBC Securities Inc. lifted its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in TG Therapeutics during the second quarter valued at $35,000. Blue Trust Inc. grew its holdings in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth about $53,000. Finally, Values First Advisors Inc. bought a new position in shares of TG Therapeutics in the 3rd quarter worth about $58,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.